New drug YL202 targets advanced cancers in Mid-Stage trial
NCT ID NCT07202364
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests an experimental drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if the drug can shrink tumors, while also checking for side effects and how the drug moves through the body. Participants will receive YL202 intravenously and be monitored for response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincial Tumor Hospital
RECRUITINGChangsha, Hunan, 410006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.